combined treatment with photodynamic therapy and

th
The 8 World Congress on
Controversies in Ophthalmology (COPHy)
Anterior Segment ● Glaucoma ● Retina
Madrid, Spain, March 30 - April 1, 2017
www.comtecmed.com/cophy
COMBINED TREATMENT WITH PHOTODYNAMIC THERAPY AND INTRAVITREAL ANTI-VGEF
INYECTION FOR CIRCUMSCRIBED CHOROIDAL HEMANGIOMA: LONG-TERM (THREE YEARS)
RESULTS
2
1
1
1
B. Domínguez García , A. José Gómez Escobar , M. Jesús Díaz Granda , F. Espejo Arjona ,
1
I. Relimpio López
1
Ophthalmology, Hospital Virgen Macarena, Spain
2
Ophthalmology, Hospital Juan Ramón Jiménez, Spain
Purpose: To evaluate the long-term efficacy of verteporfin photodynamic therapy (PDT) combined with
intravitreal anti-VGEF injections (Bevacizumab) as the primary treatment for symtomatic choroidal
hemangioma (CCH). Methods: Interventional case series. Ten subjects with CCH and evidence of exudative
macular edema changes on optical coherence tomography (OCT). Five minutes after intravenously
Verteporfin infusion, a 689 nm laser was applied with a intensity of 600 mW/cm2, light dose of 50 J/cm2 for 83
seconds. For two patients we used a intensity of 600 mW/cm2, light dose of 100 J/cm2 for 166 seconds.
Retreatment were performed in case of persistent exudation found on OCT. Results: One patient received 1
PDT sessión, Four patients received 2 PDT session at 50J/cm2. Theree eyes treated with 50J/cm2 received 3
PDT session. One patient required 4 PDTs and another patient required 5 PDTs. After a follow up of three
years, BCVA improved by 3 lines in 6 eyes, OCT showed the complete resolution of macular exudation in this
casses and all tumors responded with a reduction in size (ultrasound). In 4 eyes, visual acuity did not increase
and macular exudation on OCT was persistent. Conclusion: The theree-year results of combining PDT with
anti-VGEF injections in treating symptomatic CCH support that this treatment is effective in terms of resolution
of exudative subretinal fluid and recovery of VA in 60% of our casses, who needed 2.5 PDTs medium. In the
other patients we must consider another modalities of treatment. Case selection and prognostic factors need
to be defined so we could foresee the response to the treatment and consider another therapeutic strategy.
Financial Disclosure: No